iLoFFunding totaling $5M was raised for a digital health company with offices in Oxford, UK, and Porto, Portugal.
Faber led the $4.1m round, with participation by M12, Quiet Capital and Lunar Ventures. Alter Venture Partners, Re.Mind Capital, Fluxunit, ams OSRAM’s corporate VC arm, and Alter Venture Partners. Charlie Songhurst, an angel investor and former GM of Microsoft, participated as well as Berggruen Holdings. This family office was Nicolas Berggruen’s, a serial philanthropist investor. iLoF was also awarded a $900k grant by ERDF to help accelerate and clinically validate their mission of reducing the time and costs of recruiting patients for clinical trial recruitment.
The company plans to use the funds for ongoing engagements with global corporations in Biotech, Pharmaceutical, and Clinical.
CEO Luis Valente and CSO Paula Sampaio are leading iLoF’s AI-platform. This platform will accelerate personalized drug discovery and development. Using advanced AI and Photonics, iLoF collects massive amounts of data to create a digital library with biomarkers and biological profiles. This allows physicists, data scientists, and biologists to quickly develop life-saving personalized treatments for patients.